Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
This article was originally published in The Pink Sheet Daily
Executive Summary
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.